anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.
Incorporation of an aminosugar (e.g., glucosamine) to a preparation make a vitamin B1 stable. The content of the aminosugar is an effective amount to stabilize the vitamin B1, and is, for example, not less than 0.1 part by weight relative to 1 part by weight of the vitamin B1. Incorporation of the aminosugar can improve the disintegrativity of a solid preparation comprising a glycosaminoglycan (a hyaluronic acid, a chondroitin or a salt thereof). The content of aminosugars is not less than 0.1 part by weight relative to 1 part by weight of glycosaminoglycans. The solid preparation can inhibit forming gel masses of glycosaminoglycan and can improve the disintegrativity. Moreover, a joint disorder such as arthralgia can be improved by combination of the vitamin B1 and the glucosamine (e.g., glucosamine or a salt thereof).
Primary biliary cholangitis is a chronic, autoimmune, cholestatic disease that mainly affects women aged 40-70 years. Recent epidemiological studies have shown an increasing incidence worldwide despite geographical heterogeneity and a decrease in the female-to-male ratio of those the disease affects. Similar to other autoimmune diseases, primary biliary cholangitis occurs in genetically predisposed individuals upon exposure to environmental triggers, specifically xenobiotics, smoking, and the gut microbiome. Notably, the diversity of the intestinal microbiome is diminished in individuals with primary biliary cholangitis. The intricate interplay among immune cells, cytokines, chemokines, and biliary epithelial cells is postulated as the underlying pathogenic mechanism involved in the development and progression of primary biliary cholangitis, and extensive research has been dedicated to comprehending these complex interactions. Following the official approval of obeticholic acid as second-line treatment for patients with an incomplete response or intolerance to ursodeoxycholic acid, clinical trials have indicated that peroxisome proliferator activator receptor agonists are promising additional second-line drugs. Future dual or triple drug regimens might reach a new treatment goal of normalisation of alkaline phosphatase levels, rather than a decrease to less than 1·67 times the upper limit of normal levels, and potentially improve long-term outcomes. Improvement of health-related quality of life with better recognition and care of subjective symptoms, such as pruritus and fatigue, is also an important treatment goal. Promising clinical investigations are underway to alleviate these symptoms. Efforts to facilitate better access to medical care and dissemination of current knowledge should enable diagnosis at an earlier stage of primary biliary cholangitis and ensure access to treatments based on risk stratification for all patients.
BACKGROUND: Illness perceptions can affect the way people with musculoskeletal pain emotionally and behaviorally cope with their health condition. Understanding patients illness perceptions may help facilitate patient-centered care. The purpose of this study was to explore illness perceptions and the origin of those perceptions in people with chronic disabling non-specific neck pain seeking primary care.
METHODS: A qualitative study using a deductive and inductive analytical approach was conducted in 20 people with persistent (> 3 months) and disabling (i.e., Neck Disability Index ≥ 15) neck pain. Using a semi-structured format, participants were interviewed about their illness perceptions according to Leventhal's Common Sense Model. Purposive sampling and member checking were used to secure validity of study results.
RESULTS: Participants reported multiple symptoms, thoughts and emotions related to their neck pain, which continuously required attention and action. They felt trapped within a complex multifactorial problem. Although some participants had a broader biopsychosocial perspective to understand their symptoms, a biomedical perspective was dominant in the labelling of their condition and their way of coping (e.g., limiting load, building strength and resilience, regaining mobility, keep moving and being meaningful). Their perceptions were strongly influenced by information from clinicians. Several participants indicated that they felt uncertain, because the information they received was contradictory or did not match their own experiences.
CONCLUSION: Most participants reported that understanding their pain was important to them and influenced how they coped with pain. Addressing this 'sense making process' is a prerequisite for providing patient-centered care.
Preclinical disease models are important for the advancement of therapeutics towards human clinical trials. One of the difficult tasks of developing a well-characterized model is having a reliable modality with which to trend the progression of disease. Acute rejection is one of the most devastating complications that can occur following organ transplantation. Specifically in cardiac transplantation, approximately 12% of patients will experience at least one episode of moderate or severe acute rejection in the first year. Currently, the gold standard for monitoring rejection in the clinical setting is to perform serial endomyocardial biopsies for direct histological assessment. However, this is difficult to reproduce in a porcine model of acute rejection in cardiac transplantation where the heart is heterotopically transplanted in an abdominal position. Cardiac magnetic resonance imaging is arising as an alternative for serial screening for acute rejection in cardiac transplantation. This is an exploratory study to create and define a standardized cardiac magnetic resonance screening protocol for characterizing changes associated with the presence of acute rejection in this preclinical model of disease. Results demonstrate that increases in T1 mapping, T2 mapping, left ventricular mass, and in late gadolinium enhancement are significantly correlated with presence of acute rejection.
Laryngeal squamous cell carcinoma (LSCC) is a prevalent human cancer with a complex pathogenesis that remains incompletely understood. Here, we unveil a long non-coding RNA (lncRNA) associated with LSCC tumorigenesis and progression. LOC730101 exhibits significant overexpression in human LSCC tissues, and elevated LOC730101 levels correlate with malignant clinicopathological characteristics. Moreover, we demonstrate that LOC730101 is encapsulated into exosomes in an hnRNPA2B1-dependent manner, serving as a promising plasma biomarker for discriminating LSCC patients from healthy individuals (AUC = 0.92 with 89.36% sensitivity and 86.36% specificity). Exosomes derived from LSCC cells enhance the viability, DNA synthesis rate, and invasiveness of normal nasopharynx epithelial cells, with pronounced effects observed upon LOC730101 overexpression. Additionally, exosomal LOC730101 promotes tumor growth in vivo. Mechanistically, exosomal LOC730101 internalization by normal nasopharynx epithelial cells leads to increased H3K4me3 levels on the p38 MAPK gamma (p38γ) promoter via direct interaction with hnRNPA2B1. This interaction activates p38γ transcription, ultimately driving LSCC tumorigenesis. Collectively, our findings uncover a novel exosomal lncRNA that mediates communication between normal and LSCC cells during LSCC carcinogenesis, suggesting that targeting LOC730101 may represent a promising therapeutic strategy for LSCC treatment.
1,147,210. Vitamin beadlets. EASTMAN KODAK CO. 24 June, 1966 [30 June, 1965], No. 28352/66. Heading A5B. A process for making a dry, free flowing, finely divided, fat-soluble vitamin-active product, comprises (1) preparing a colloidal solution of cold water dispersible, non-gelling colloid material and water; (2) dispersing in said colloidal solution a water insoluble, fat soluble vitamin active composition to form a first dispersion; (3) dispersing the latter in a water immiscible liquid dispersing medium to form a second dispersion; (4) extracting water at - 10 to 0‹C from the latter with a water extraction agent until droplets of the first dispersion solidify to form particles; (5) separating the latter from the dispersing medium and water extraction agent at -10 to 0‹C; and (6) removing residual moisture from the solid particles. Lecithin may be added as a stabilising agent to the second dispersion. The colloid material may be gum acacia, gum ghatti, amylopectin, pre-gelatinised and thin boiling starches, substituted starches, e.g. corn starch which has 'been partially reacted with octenyl succinic anhydride, or mixtures thereof. Water soluble, edible, plasticizers e.g. glucose, sucrose, dextrose, lactose, and corn syrup may 'be used with the colloid material. The vitamin-active composition consists of at least one water insoluble, fat soluble, vitamin active compound e.g. vitamin A, D, E, and K compounds. The compounds may be in solution or suspended in oil. The vitamin active composition may 'be liquid, solid, or a mixture of solids and liquid. An antioxidant may be incorporated in the vitamin active composition. The water immiscible dispersing medium may be mineral oil. Specified water extracting agents are methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, 1,4-dioxan, pyridine, and mixtures thereof. The particles may be separated from the dispersing medium by filtration and washed with additional water extraction agent and then with a solvent for the dispersing medium e.g. hexane when the medium is mineral oil. Residual moisture may be removed by air drying, for instance, using a fluidised bed.
The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
A 78-year-old male on warfarin for deep venous thrombosis is referred to us for resection of a sessile polyp in the cecum. A high-definition Fujifilm BL-7000 processor, virtual chromoendoscopy, and EC-760ZP-V/L magnifying endoscope were used. Diathermy source, ERBE VIO 3. Auto cut mode, Effect 5, 80 watts, and Soft coagulation mode, Effect 5, 60 watts. Underwater polypectomy ensued with resection in two fragments. The resection bed was invaginated into the appendiceal orifice, hence no other measures were considered to prevent delayed bleeding. No complications were reported. The histopathological study found a tubulovillous adenoma with lesion-free borders.
11,215. Imray. O., [Society of Chemical Industry in Basle]. Aug. 3. Albumens.-A lipoid blood-coagulating substance is obtained from alcoholic blood extracts by the following process: the bulk of the alcohol is distilled off at a low temperature, the residue is mixed with water, the resulting emulsion is agitated with a chlorhydrocarbon, and from the solution so obtained the required product is precipitated by adding acetone; the precipitate is extracted with ether, and the ethereal solution is evaporated in vacuo. According to an example, chloroform is the chlorhydrocarbon used; tetrachlorethane, ethylene dichloride, perchlorethane, and carbon tetrachloride are also specified as suitable.
PURPOSE:To obtain a sheet for skin sanitation, having antimicrobial properties for indigenous bacteria on the skin and useful especially for preventing the onset of common acne by subjecting a complex porous substance composed of chitin or chitosan and a fibrous substance to acetylating treatment. CONSTITUTION:A porous sheet is obtained by dissolving chitin or chitosan in an acidic solution (e.g. acetic acid), adding fiber, etc., (e.g. paper pulp), providing a porous substance, preferably by freeze-drying at -20 to -40 deg.C and then immersing the porous substance in a solution such as acetic anhydride or exposing the porous substance to a gaseous atmosphere and thereby carrying out acetylation. The weight ratio of the chitin or chitosan to fibrous substance used is (1:0.5) to (1:5). Indigenous bacteria on the skin such as causative bacteria of common acne can be killed or their growth can be suppressed by contact with the skin.
PCT No. PCT/GB96/01093 Sec. 371 Date May 14, 1998 Sec. 102(e) Date May 14, 1998 PCT Filed May 7, 1996 PCT Pub. No. WO96/34890 PCT Pub. Date Nov. 7, 1996The inhibitors, obtainable from tissue or secretions of leeches typically of the order Rhynchobdellida, has the following terminal sequence: NH2-Lys-Leu-Leu-Pro-Cys-Lys-Glu-Y-His-Gln-Gly-Ile-Pro-Asn-Pro-Arg- wherein Y represents any amino acid sequence; or a pharmaceutically acceptable salt, derivative or bioprecursor of said sequence, or an analogue or homologue thereof. Because of their extreme potency in the nanomolar range, they can be used to treat a number of diseases where protein cross-linking is important. They can be used for the treatment of Crohn's disease, tumor implantation, atherosclerosis, thrombotic microangiophathy, fibrous growths of the skin, acne, scar formation, membranous glomerulonephrits, cataracts, or infection with microfilarial nematodes. In particular, they can be used to reduce the stability of thrombi so that they are more susceptible to lysis by thrombolytic agents.
PURPOSE: To investigate underlying co-mechanisms of PCOS and periodontitis through transcriptomic approach.
METHODS: PCOS and periodontitis gene expression data were downloaded from the GEO database to identify differentially expressed genes. GO and KEGG pathway enrichment analysis and random forest algorithm were used to screen hub genes. GSEA analyzed the functions of hub genes. Correlations between hub genes and immune infiltration in two diseases were examined, constructing a TF-ceRNA regulatory network. Clinical samples were gathered from PCOS and periodontitis patients and RT-qPCR was performed to verify the connection.
RESULTS: There were 1661 DEGs in PCOS and 701 DEGs in periodontitis. 66 intersected genes were involved and were enriched in immune and inflammation-related biological pathways. 40 common genes were selected from the PPI network. RF algorithm demonstrated that ACSL5, NLRP12, CCRL2, and CEACAM3 were hub genes, and GSEA results revealed their close relationship with antigen processing and presentation, and chemokine signaling pathway. RT-qPCR results confirmed the upregulated gene expression in both PCOS and periodontitis.
CONCLUSION: The 4 hub genes ACSL5, NLRP12, CCRL2, and CEACAM3 may be diagnostic genes for PCOS and periodontitis. The created ceRNA network could provide a molecular basis for future studies on the association between PCOS and periodontitis.
The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its variant for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition is also characterized in that its particle size falls between 0.1 and 10 mum. The composition produced by the method of the present invention is effective in suppressing infections caused by viruses, bacteria and fungi. Since the composition is developed in a form suitable for inhalation, it can directly provide the active ingredient to the sites of infection from these microbes, and thus treat and prevent respiratory infections and external wounds. The composition of the present invention is also available for incorporation into other vehicles to form tablets.
PURPOSE:To prepare the titled factor useful for the remedy of cancer, in high yield, by culturing the fibroblast cell of animal in a culture liquid containing phorbols or virus, and collecting the factor accumulated in the cultured product. CONSTITUTION:Fibroblast cell of an animal (e.g. man, mouse, etc.) is cultured in a culture liquid containing phorbols (e.g. phorbol, phorbol myristate, etc.) or virus (e.g. SV40), and RPMI 1640 medium containing bovine fetus serum etc., and the T-cell activation factor accumulated in the cultured product is collected therefrom. The cultivation is carried out by usual liquid cultivation with aeration, preferably at 25-40 deg.C and 7.5-8.3pH. The concentration of phorbol is usually 1-1,000ng per 1ml of the culture liquid, and that of the virus is 10- 1,000 per one cell. The T-cell activation factor activates the DNA synthesis of T-lymphocyte, and is expected to be a remedy for cancer and other diseases.
Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
The investigators will recruit 40 gastric cancer patients who underwent D2 lymphadenectomy and histologically verified as stage ⅢB or ⅢC according to the seventh edition of the TNM classification for gastric cancer. When these patients have completed 8 cycles of Xelox as adjuvant chemotherapy without any recurrence, they will randomly assigned to group A or B. Each group possesses 20 gastric cancer patients finally. Patients in group A will receive the best supportive care，and take Apatinib 500mg/qd orally, 28 days as a cycle, till disease progresses. Patients in group B will receive the best supportive care. Through follow-up and statistics, the investigators will observe whether Apatinib can improve the disease free survival (DFS) of gastric cancer patients with stage IIIb\&IIIC. Meanwhile, the investigators also will observe whether the Apatinib can improve the overall survival (OS) and estimate the quality of life of patients have taken the Apatinib.
Patients will receive stellate ganglion block and local anesthetic using an ultrasound-guided technique.After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the lateral position toward the anterior aspect of longus colli muscle just posterior to the internal jugular vein. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 10 mL of 0.2% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
Techniques that facilitate improved medical condition diagnostics are provided. An example embodiment can include a device. The device can include a memory that stores computer executable components and a processor. The processor can execute the computer executable components stored in the memory. The computer executable components can include training logic component and a determination logic component. The training logic component can generate a prediction model. The prediction model can generate \predict diagnosis based on electronic healthcare record data and image data of a known patient. The determination logic component can determine whether the predicted diagnosis exceeds an accuracy threshold value.
Participants in Asia Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
Thio alkanoyl-carnitines of formula (I) are prepd. by a compd. of formula R1COSH with a compd. of formula (II).  In the formulas, R is C2-6 branched or straight alkylene; R1 is C1-4 branched or straight lower alkyl; X- is halogen; n is 0-4.  (I) have a mucolytic and anti- tussive activity improving properties of sputum and are used in the treatment of diseases of a respiratory tract.
The quantity of beef will be adjusted or normalized based on their individual energy requirements. The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal. Participants will consume meals for six weeks.
A hangover reducing composition containing a lactic acid bacteria fermented substance of Ssangwha-tang is provided to lower blood alcohol concentration. A hangover reducing composition comprises a lactic acid bacteria fermented substance of Ssangwha-tang which is prepared by inoculating lactic acid bacteria to the Ssangwha-tang and fermenting it. The Ssangwha-tang is obtained by mixing 10 parts of Paeonia lactiflora, 6-17 parts of Prepared Rehmannia Root, 6-17 parts of Astragalus membranaceus, 6-17 parts of Angelica sinensis, 6-17 parts of Cnidium officinale, 3-14 parts of Cinnamomum loureirii, 3-14 parts of Glycyrrhiza uralensis, 2-14 parts of Rhizoma Zingiberis and 4-8 parts of Zizyphi Fructus and extracting the mixture in hot water. The lactic acid bacteria are selected from the group consisting of Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus acidophilus and Lactobacillus rhamnosus. The hangover reducing composition lowers blood alcohol concentration before or after alcohol ingestion. The hangover reducing composition is provided as a health food.
Inotuzumab ozogamicin has been studied as a single agent in refractory and relapsed ALL. In the relapsed setting, inotuzumab ozogamicin has been shown to achieve complete remission (CR) in 81% of patients and minimal residual disease (MRD) negativity in 78% of patients who achieve CR. In the proposed study, escalating doses of inotuzumab ozogamicin will be added to a standard pediatric inspired re-induction regimen and administered to patients with relapsed or refractory B-cell ALL. Two re-induction regimens will be tested. The first regimen is a 3-drug regimen comprised of prednisone, vincristine, and daunorubicin. The second is a 4-drug regimen comprised of prednisone, vincristine, daunorubicin, and pegaspargase. Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-ARA-C) will be included for central nervous system (CNS) prophylaxis with both the 3-drug and 4-drug regimens. We hypothesize that combining inotuzumab ozogamicin with these regimens is safe and will improve CR rates, successful transition to allo HCT, and overall survival in patients with relapsed or refractory B-ALL.
Venous thrombosis (VT) is a serious medical condition in which a blood clot forms in deep veins, often causing limb swelling and pain. Current antithrombotic therapies carry significant bleeding risks resulting from targeting essential coagulation factors. Recent advances in this field have revealed that the cross talk between the innate immune system and coagulation cascade is a key driver of VT pathogenesis, offering new opportunities for potential therapeutic interventions without inducing bleeding complications. This review summarizes and discusses recent evidence from preclinical models on the role of inflammation in VT development. We highlight the major mechanisms by which endothelial cell activation, Weibel-Palade body release, hypoxia, reactive oxygen species, inflammasome, neutrophil extracellular traps, and other immune factors cooperate to initiate and propagate VT. We also review emerging clinical data describing anti-inflammatory approaches as adjuncts to anticoagulation in VT treatment. Finally, we identify key knowledge gaps and future directions that could maximize the benefit of anti-inflammatory therapies in VT. Identifying and targeting the inflammatory factors driving VT, either at the endothelial cell level or within the clot, may pave the way for new therapeutic possibilities for improving VT treatment and reducing thromboembolic complications without increasing bleeding risk.